IL6 and keloid: Utilizing keloid-derived precursor cells transplanted subcutaneously in immunocompromised mice a human keloid-like tumor model that is driven by the in vivo inflammatory niche and allows testing of the anti-tumor therapeutic effect of antibodies targeting distinct niche components, specifically IL-6 and IL-17.